Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.
Eur Arch Otorhinolaryngol. 2013 Jan;270(1):293-9. doi: 10.1007/s00405-012-2008-5. Epub 2012 Apr 3.
The optimal treatment of sinonasal undifferentiated carcinoma (SNUC) remains unclear. We report our results on the outcome and toxicity of patients with SNUC treated by a combined modality and attempt to define the optimal treatment strategies by reviewing the literature. Between 1996 and 2010, 21 consecutive patients with SNUC were treated by any combination of surgery, chemotherapy and radiotherapy. End points were local control (LC), regional control (RC), disease-free (DFS), cause-specific (CSS) overall survival (OS), and late toxicity. Organ preservation was defined as visual preservation without orbital exenteration. After median follow-up of 54 months, the 5-year actuarial rates of LC, RC, DFS, CSS, and OS were 80, 90, 64, 74, and 74 % respectively. On multivariate analysis, T-stage and multimodality treatment approach correlated significantly with LC. Elective nodal irradiation was given to 42 % of high-risk node-negative patients. None of them developed regional failure. The overall 5-year incidence of grade ≥ 2 late toxicity was 30 %. Treatment-related blindness was significantly decreased in patients treated with intensity-modulated radiotherapy (IMRT), compared to 2D and 3D-conformal radiotherapy (3DCRT), with organ preservation rates of 86 and 14 % respectively (p = 0.006). We concluded that combined-modality treatment with three, or at least two, modalities resulted in good LC, but with high overall rate of late toxicity. However, the incidence of late toxicity and permanent visual impairment were decreased over time by the introduction of IMRT. Because of the improvement in therapeutic ratio achieved by using IMRT, this highly conformal radiation technique should be the standard of care in patients with SNUC.
鼻腔鼻窦未分化癌(SNUC)的最佳治疗方法仍不清楚。我们报告了采用联合治疗模式治疗 SNUC 患者的结果和毒性,并通过文献复习尝试确定最佳治疗策略。1996 年至 2010 年期间,21 例连续 SNUC 患者接受了手术、化疗和放疗的任何联合治疗。终点为局部控制(LC)、区域控制(RC)、无疾病(DFS)、疾病特异性(CSS)总生存(OS)和迟发性毒性。保存器官定义为无眼眶内容物切除的视力保存。中位随访 54 个月后,LC、RC、DFS、CSS 和 OS 的 5 年累积生存率分别为 80%、90%、64%、74%和 74%。多变量分析显示,T 分期和多模式治疗方法与 LC 显著相关。42%的高危淋巴结阴性患者行选择性淋巴结照射,均未发生区域失败。总共有 30%的患者发生 5 年≥2 级迟发性毒性。与二维和三维适形放疗(3DCRT)相比,接受调强放疗(IMRT)治疗的患者治疗相关失明显著减少,器官保存率分别为 86%和 14%(p = 0.006)。我们得出结论,采用三种或至少两种模式的联合治疗模式可获得良好的 LC,但总体迟发性毒性发生率较高。然而,随着时间的推移,通过引入 IMRT,迟发性毒性和永久性视力损害的发生率降低。由于采用 IMRT 可提高治疗效果,因此这种高度适形的放射技术应成为 SNUC 患者的标准治疗方法。